Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes in Chicago from June 3-7, 2022. Tempus is presenting fourteen abstracts, including one oral presentation, two poster discussions, and eleven poster presentations. “The re...
Tempus, a leader in artificial intelligence and precision medicine, today announced the acquisition of Highline Sciences, a specialized, full-service clinical contract research organization (CRO) focused on oncology. Highline Sciences manages and executes on early and late-stage clinical trials, applying a customized approach to each study. Highline’s capabilities and expertise will he...
Tempus, a leader in artificial intelligence and precision medicine, today announced the commencement of an open label phase II study, in collaboration with GlaxoSmithKline (GSK) to evaluate the efficacy and safety of ZEJULA (niraparib), a poly (ADP-ribose) polymerase (PARP) inhibitor used for patients with advanced or metastatic solid tumors and a germline...
Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen). The expanded scope is anchored in new AI-based work, in which Tempus will collaborate with a multidisciplinary team of data scientists at Janssen to enhance the discov...
Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips Tempus, a leader in artificial intelligence and precision medicine, today announced that it will incorporate data from both the Memor...
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics...
Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each...
Tempus, a leader in artificial intelligence and precision medicine, today announced the submission of a Premarket Approval (PMA) application for its proprietary broad-panel DNA sequencing assay to the U.S. Food and Drug Administration (FDA). Tempus is seeking approval for its xT-Onco assay, a broad-panel next-generation sequencing-based, in vitro di...
Tempus, a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform. The study demonstrates how the platform has the potential to accelerate the application of patient derived biological models (organoids) in precision oncology...
Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of six new hires to the leadership team, including a new Chief Commercial Officer, Chief Financial Officer, General Counsel, and the company’s first Chief Accounting Officer, Senior Vice President of Marketing, and Senior Vice President of Cor...